+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07649304

Study of Glofitamab Combined with Chemoimmunotherapy for Newly Diagnosed HIV-Associated Large B-Cell Lymphoma

Led by National Cancer Institute (NCI) · Updated on 2026-10-28

15

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the combination of glofitamab with a chemoimmunotherapy regimen called R-CHOP in patients newly diagnosed with HIV-associated large B-cell lymphoma. This phase I trial aims to assess the safety, feasibility, and side effects of this regimen. Glofitamab is a bispecific antibody designed to help the immune system target cancer cells by binding to two specific proteins on their surface, while R-CHOP includes several chemotherapy drugs and rituximab, another antibody targeting cancer cells. Participants receive R-CHOP, which consists of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, given intravenously or orally over specific times and days in 21-day cycles for up to 6 cycles. Glofitamab is administered intravenously on days 8 and 15 of the second cycle and on day 8 of subsequent cycles, up to 8 cycles if there is no disease progression or unacceptable side effects. During the study, patients may also undergo tumor biopsies, bone marrow biopsies or aspirations, echocardiograms, PETCT scans, and blood sample collections. Participants are monitored for response to treatment and side effects with regular scans and laboratory tests. The main outcome measured is the ability to complete at least 4 full cycles of the combined treatment. Secondary outcomes include response rates, survival rates, and toxicity over time. After completing treatment, patients are followed every 3 months to assess ongoing health and disease status. The trial is sponsored by the National Cancer Institute and will continue until December 2028.

CONDITIONS

Brief Title

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here